Revolutionary gel-based solutions for interventional radiology
Understanding our revolutionary gel-based technology
NovaSeal® is composed of a biocompatible polymer mixture and loaded with a contrast agent that transitions from a liquid to a gel state at a critical temperature.
Packaged in a sterile syringe with a standard Luer lock tip, it is injected into a target vessel via intravascular catheters under real-time imaging guidance.
Upon injection, NovaSeal forms a hydrogel embolus, creating a mechanical barrier that occludes blood flow to the target area.
The formed hydrogel creates a precise mechanical barrier that effectively blocks blood supply to hypervascular tumors, starving cancer cells of oxygen and nutrients.
NovaSeal® is designed to treat a range of conditions requiring precise blood vessel blockage
Targeted treatment for liver cancer with minimal damage to healthy tissue. Our gel-based approach ensures precise embolization of tumor blood vessels.
Effective embolization for kidney cancer treatment. Our technology provides controlled and sustained occlusion of renal tumor vessels.
Precise treatment for hypervascular brain tumors. Our gel technology ensures accurate delivery without affecting surrounding brain tissue.
Non-surgical treatment for uterine fibroids. Our minimally invasive approach provides effective symptom relief without major surgery.
Minimally invasive treatment for prostate conditions. Our technology offers a safe alternative to traditional surgical procedures.
What makes NovaSeal® superior to traditional embolic agents
Composed of biocompatible and biodegradable polymers ensuring safety and minimizing long-term foreign body reactions.
By eliminating toxic materials like DMSO and tantalum, NovaSeal® minimizes environmental impact and patient risk.
Packaged as a ready-to-use product, eliminating the need for complex and time-consuming preparation steps in hospitals.
The injection is painless, addressing the significant pain that often requires patients to undergo anesthesia with other products.
Using a contrast agent and imaging techniques allows for real-time monitoring of treatment effectiveness and strategy adjustment.
Leveraging advanced technologies and meticulous design, we prevent unintended embolization, enhancing precision in treating hypervascular tumors.
Ongoing projects and clinical trials
We are currently designing our animal studies to further validate the safety and efficacy of NovaSeal®. Our research team is working on comprehensive preclinical evaluations to ensure the highest standards of patient safety and treatment effectiveness.
Our development pipeline includes advanced formulations and next-generation embolic agents that will expand our treatment capabilities and improve patient outcomes across a broader range of conditions.
In vitro and in vivo validation
Safety and efficacy evaluation
First-in-human studies
NovaSeal® Development
Preclinical Studies
Animal Studies
Clinical Trials